Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank-check company formed to pursue a business combination in the pharmaceutical and domestic drug manufacturing sector. The SPAC, operating under the Drugs Made In America acquisition platform, filed a Form 10-Q with the SEC on May 14, 2026, under accession number 0001213900-26-056651, indicating it remains an active development-stage vehicle. As a follow-on vehicle for its sponsor team, DMII targets opportunities in domestic pharma supply chains and related life sciences industries. For full filing history, deal timeline, and peer benchmarks on DMII, sign up for complete data access at SpacDesk.